Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125825752 | 12582575 | 2 | F | 201212 | 20160725 | 20160722 | 20160801 | EXP | PHHY2013MX059482 | NOVARTIS | 76.12 | YR | F | Y | 65.00000 | KG | 20160801 | MD | MX | MX |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125825752 | 12582575 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 9.5 MG (PATCH 10CM2), QD | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||||||
| 125825752 | 12582575 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 4.6 MG (PATCH 5CM2), QD | 22083 | 4.6 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||||||
| 125825752 | 12582575 | 3 | SS | EXELON PATCH | RIVASTIGMINE | 1 | 22083 | TRANS-THERAPEUTIC-SYSTEM | |||||||||||
| 125825752 | 12582575 | 4 | SS | EXELON PATCH | RIVASTIGMINE | 1 | 22083 | TRANS-THERAPEUTIC-SYSTEM | |||||||||||
| 125825752 | 12582575 | 5 | SS | EXELON PATCH | RIVASTIGMINE | 1 | 22083 | TRANS-THERAPEUTIC-SYSTEM | |||||||||||
| 125825752 | 12582575 | 6 | SS | EXELON PATCH | RIVASTIGMINE | 1 | 22083 | TRANS-THERAPEUTIC-SYSTEM | |||||||||||
| 125825752 | 12582575 | 7 | SS | EXELON PATCH | RIVASTIGMINE | 1 | 22083 | TRANS-THERAPEUTIC-SYSTEM | |||||||||||
| 125825752 | 12582575 | 8 | C | AKINETON | BIPERIDEN HYDROCHLORIDE | 1 | Unknown | 100 MG, UNK | U | 0 | 100 | MG | |||||||
| 125825752 | 12582575 | 9 | C | OLANZAPINE. | OLANZAPINE | 1 | Oral | 10 MG, QD (3 YEARS AGO) | 0 | 10 | MG | CAPSULE | QD | ||||||
| 125825752 | 12582575 | 10 | C | ASPIRIN PROTECT | ASPIRIN | 1 | Unknown | U | 0 | ||||||||||
| 125825752 | 12582575 | 11 | C | INSULEX | 2 | Subcutaneous | 24 IU, QD (20 YEARS AGO) | 0 | 24 | IU | QD | ||||||||
| 125825752 | 12582575 | 12 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 20 MG, QD ( (3 YEARS AGO) | 0 | 20 | MG | CAPSULE | QD | ||||||
| 125825752 | 12582575 | 13 | C | ENALAPRIL | ENALAPRIL | 1 | Unknown | UNK | U | 0 | |||||||||
| 125825752 | 12582575 | 14 | C | CONCOR | BISOPROLOL FUMARATE | 1 | Unknown | UNK | U | 0 | |||||||||
| 125825752 | 12582575 | 15 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG, QD (3 YEARS AGO) | 0 | 75 | MG | QD | |||||||
| 125825752 | 12582575 | 16 | C | METOPROLOL. | METOPROLOL | 1 | Oral | 0.5 DF, (3 YEARS AGO) | 0 | .5 | DF | TABLET | QD | ||||||
| 125825752 | 12582575 | 17 | C | PENTOXYFYLLINE | 2 | Unknown | UNK | U | 0 | ||||||||||
| 125825752 | 12582575 | 18 | C | ALLOPURINOL. | ALLOPURINOL | 1 | Unknown | UNK | U | 0 | |||||||||
| 125825752 | 12582575 | 19 | C | VITAMIN B | VITAMIN B | 1 | Unknown | UNK | U | 0 | |||||||||
| 125825752 | 12582575 | 20 | C | IRON | IRON | 1 | Unknown | UNK | U | 0 | |||||||||
| 125825752 | 12582575 | 21 | C | ATORVASTATIN | ATORVASTATIN | 1 | Unknown | UNK | U | 0 | |||||||||
| 125825752 | 12582575 | 22 | C | NITROFURANTOIN. | NITROFURANTOIN | 1 | Oral | 100 MG, QD (3 YEARS AGO) | 0 | 100 | MG | TABLET | QD | ||||||
| 125825752 | 12582575 | 23 | C | NALIDIXIC ACID | NALIDIXIC ACID | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125825752 | 12582575 | 1 | Vascular dementia |
| 125825752 | 12582575 | 2 | Parkinson's disease |
| 125825752 | 12582575 | 3 | Dementia Alzheimer's type |
| 125825752 | 12582575 | 4 | Aphasia |
| 125825752 | 12582575 | 5 | Disorientation |
| 125825752 | 12582575 | 6 | Cerebrovascular accident |
| 125825752 | 12582575 | 7 | Cerebral infarction |
| 125825752 | 12582575 | 8 | Parkinson's disease |
| 125825752 | 12582575 | 9 | Schizophrenia |
| 125825752 | 12582575 | 10 | Cerebrovascular accident prophylaxis |
| 125825752 | 12582575 | 11 | Diabetes mellitus |
| 125825752 | 12582575 | 12 | Gastritis prophylaxis |
| 125825752 | 12582575 | 13 | Product used for unknown indication |
| 125825752 | 12582575 | 14 | Product used for unknown indication |
| 125825752 | 12582575 | 15 | Product used for unknown indication |
| 125825752 | 12582575 | 16 | Hypertension |
| 125825752 | 12582575 | 17 | Product used for unknown indication |
| 125825752 | 12582575 | 18 | Product used for unknown indication |
| 125825752 | 12582575 | 19 | Product used for unknown indication |
| 125825752 | 12582575 | 20 | Product used for unknown indication |
| 125825752 | 12582575 | 21 | Product used for unknown indication |
| 125825752 | 12582575 | 22 | Product used for unknown indication |
| 125825752 | 12582575 | 23 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125825752 | 12582575 | Application site burn | |
| 125825752 | 12582575 | Application site exfoliation | |
| 125825752 | 12582575 | Application site injury | |
| 125825752 | 12582575 | Application site irritation | |
| 125825752 | 12582575 | Application site laceration | |
| 125825752 | 12582575 | Application site pain | |
| 125825752 | 12582575 | Application site pruritus | |
| 125825752 | 12582575 | Application site scar | |
| 125825752 | 12582575 | Product use issue | |
| 125825752 | 12582575 | Prosopagnosia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125825752 | 12582575 | 1 | 201212 | 201507 | 0 | |
| 125825752 | 12582575 | 2 | 201507 | 0 |